{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:10:02Z","timestamp":1756289402395,"version":"3.44.0"},"reference-count":35,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,9,2]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Subcutaneous panniculitis-like T cell lymphoma (SPTCL) is a rare cutaneous T cell malignancy of cytotoxic T cell origin. It is frequently associated with autoimmune diseases. It is known to preferentially involve subcutaneous adipose tissue and histologically resembles lupus panniculitis. The aetiology and risk factors of SPTCL are unclear and there are limited studies available since this entity was initially described in 2001. There are even fewer case reports describing the association between SPTCL and chronic lymphocytic leukemia (CLL). In this article, we present a case of SPTCL arising during treatment for CLL. We conducted an extensive review of literature to delve into the possible risk factors for SPTCL development in association with CLL, including pre-existing haematological malignancies, autoimmune conditions, immunomodulation and immunosuppressive chemotherapy.<\/jats:p>","DOI":"10.1136\/bcr-2021-243490","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T13:09:27Z","timestamp":1632748167000},"page":"e243490","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous panniculitis-like T cell lymphoma arising in association with chronic lymphocytic leukaemia"],"prefix":"10.1136","volume":"14","author":[{"given":"Lakshmi Shree","family":"Kulumani Mahadevan","sequence":"first","affiliation":[{"name":"Department of Anatomic and Clinical Pathology, Georgetown University Medical Center, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metin","family":"Ozdemirli","sequence":"additional","affiliation":[{"name":"Department of Anatomic and Clinical Pathology, Georgetown University Medical Center, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"2025082702410247000_14.9.e243490.1","unstructured":"Swerdlow S , Campo E , Harris N . WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer: Lyon, 2017."},{"key":"2025082702410247000_14.9.e243490.2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-56352-2_1"},{"key":"2025082702410247000_14.9.e243490.3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12185-010-0642-5","article-title":"Epstein\u2013Barr virus-infected subcutaneous panniculitis-like T-cell lymphoma associated with methotrexate treatment","volume":"92","author":"Nemoto","year":"2010","journal-title":"Int J Hematol"},{"key":"2025082702410247000_14.9.e243490.4","unstructured":"Jaffe ES , Arber DA , Campo E . Hematopathology. 2nd edn. Philadelphia, PA: Elsevier, 2017: 1199."},{"key":"2025082702410247000_14.9.e243490.5","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/ijd.13653","article-title":"Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma","volume":"56","author":"Chang","year":"2017","journal-title":"Int J Dermatol"},{"key":"2025082702410247000_14.9.e243490.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2012.12.011"},{"key":"2025082702410247000_14.9.e243490.7","doi-asserted-by":"crossref","DOI":"10.1093\/ajcp\/142.suppl1.127","article-title":"Subcutaneous Panniculitis-like T-cell lymphoma with Hemophagocytosis in a patient with chronic lymphocytic leukemia post Fludarabine-Cyclophosphamide-Rituximab chemotherapy","volume":"142","author":"Wang","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"2025082702410247000_14.9.e243490.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.023"},{"key":"2025082702410247000_14.9.e243490.9","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199101000-00002"},{"key":"2025082702410247000_14.9.e243490.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-087288"},{"key":"2025082702410247000_14.9.e243490.11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/DAD.0000000000001173","article-title":"Subcutaneous Panniculitis-Like T-cell lymphoma versus lupus erythematosus panniculitis: distinction by means of the Periadipocytic cell proliferation index","volume":"40","author":"Sitthinamsuwan","year":"2018","journal-title":"Am J Dermatopathol"},{"key":"2025082702410247000_14.9.e243490.12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0190-9622(95)91430-7","article-title":"A clinical and histologic mycosis fungoides simulant occurring as a T-cell infiltrate coexisting with B-cell leukemia cutis","volume":"33","author":"Metzman","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"2025082702410247000_14.9.e243490.13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.1993.tb03171.x","article-title":"Clonal chronic lymphocytic leukaemia-like B lymphocytes in the blood of patients with cutaneous T-cell disorders","volume":"85","author":"Daenen","year":"1993","journal-title":"Br J Haematol"},{"key":"2025082702410247000_14.9.e243490.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08226.x"},{"key":"2025082702410247000_14.9.e243490.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1992.tb14852.x"},{"key":"2025082702410247000_14.9.e243490.16","doi-asserted-by":"publisher","DOI":"10.1053\/adpa.2002.33904"},{"key":"2025082702410247000_14.9.e243490.17","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/ijd.12063","article-title":"Cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia: clinical characteristics, temporal relationships, and survival data in a series of 14 patients at Mayo clinic","volume":"53","author":"Chang","year":"2014","journal-title":"Int J Dermatol"},{"key":"2025082702410247000_14.9.e243490.18","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1986.01660170098028"},{"key":"2025082702410247000_14.9.e243490.19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03679.x"},{"key":"2025082702410247000_14.9.e243490.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07346.x"},{"key":"2025082702410247000_14.9.e243490.21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000109362","article-title":"S\u00e9zary syndrome coexisting with B-cell chronic lymphocytic leukemia: case report and review of the literature","volume":"216","author":"Karsai","year":"2008","journal-title":"Dermatology"},{"key":"2025082702410247000_14.9.e243490.22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0190-9622(90)70272-J","article-title":"Simultaneous occurrence of cutaneous T cell lymphoma and low-grade B cell lymphoproliferative diseases. A report of two cases","volume":"23","author":"Allu\u00e9","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"2025082702410247000_14.9.e243490.23","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1182\/blood.V62.6.1176.1176","article-title":"Coincidence of B-cell chronic lymphocytic leukemia and cutaneous T-cell lymphoma (mycosis fungoides): immunologic characterization by monoclonal antibodies","volume":"62","author":"Sheibani","year":"1983","journal-title":"Blood"},{"key":"2025082702410247000_14.9.e243490.24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.3.659"},{"key":"2025082702410247000_14.9.e243490.25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"2025082702410247000_14.9.e243490.26","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-2133.2009.09044.x","article-title":"Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis","volume":"160","author":"Michot","year":"2009","journal-title":"Br J Dermatol"},{"key":"2025082702410247000_14.9.e243490.27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3816\/CLM.2006.n.008","article-title":"Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy","volume":"6","author":"Berthelot","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"2025082702410247000_14.9.e243490.28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010068","article-title":"Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL","volume":"21","author":"Mhibik","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025082702410247000_14.9.e243490.29","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","article-title":"T-cells in chronic lymphocytic leukemia: guardians or drivers of disease?","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia"},{"key":"2025082702410247000_14.9.e243490.30","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0320(20000615)42:3<188::AID-CYTO5>3.0.CO;2-Q"},{"key":"2025082702410247000_14.9.e243490.31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3747\/co.27.6795","article-title":"Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia","volume":"27","author":"Banerji","year":"2020","journal-title":"Current Oncology"},{"key":"2025082702410247000_14.9.e243490.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"2025082702410247000_14.9.e243490.33","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-117618","article-title":"More than a Btk inhibitor; ibrutinib profoundly impacts the function of cell mediated immunity","volume":"132","author":"Sharpe","year":"2018","journal-title":"Blood"},{"key":"2025082702410247000_14.9.e243490.34","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jamaoncol.2015.0457","article-title":"Panniculitis in patients undergoing treatment with the Bruton tyrosine kinase inhibitor ibrutinib for lymphoid leukemias","volume":"1","author":"Fabbro","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025082702410247000_14.9.e243490.35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological toxicities of Bruton's tyrosine kinase inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am J Clin Dermatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-243490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:41:16Z","timestamp":1756287676000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-243490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,27]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bcr-2021-243490"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-243490","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}